Bagsværd, Denmark, 15 May 2023 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
1 Details of the person discharging managerial responsibilities/person closely associated a)Name of the Board member/Executive/Associated PersonHenrik Wulff2 Reason for the notificationa)Position/statusExecutive Vice President, head of Product Supply, Quality & ITb)Initial notification/AmendmentInitial notification3 Details of the issuera)NameNovo Nordisk A/Sb)LEI549300DAQ1CVT6CXN3424 Details of the transaction(s)a)Description of the financial instrument,
type of instrument,Shares
Identification codeNovo Nordisk B DK0060534915b)Nature of the transactionSale of sharesc)Price(s) and volume(s) Price(s)Volume(s) DKK 1,160.0010,000 shares d)Aggregated information Aggregated volumePrice
10,000 shares
DKK 1,160.00e)Date of the transaction2023-05-12f)Place of the transactionNasdaq Copenhagen
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 57,100 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.
Contact for further information
Media: Ambre James-Brown
+45 3079 9289
[email protected]
Natalia Salomao Abrahao (US)
+1 848 304 1027
[email protected]
Investors: Daniel Muusmann Bohsen
+45 3075 2175
[email protected]
Jacob Martin Wiborg
